Literature DB >> 10622461

Angiotropic large B-cell lymphoma with clinical features resembling subacute combined degeneration of the cord.

W S Waring1, S B Wharton, R Grant, M McIntyre.   

Abstract

Angiotropic large cell lymphoma is a rare neoplastic disorder associated with a high mortality. The hallmark of the disease is lymphoid proliferation confined to the intravascular compartment without local tissue or vessel wall infiltration [1]. This feature is so striking that the disease was originally thought to arise from endothelial tissue and early cases were described as malignant angioendotheliomatosis. However, application of immunohistochemical methods for detection of lymphoid markers such as the CD45 and CD20 cell surface markers has confirmed its lymphoid origin, usually of B-cell lineage [2]. Clinical manifestations of the disease are protean and are due to multifocal medium and small vessel occlusion by tumour cells [3]. Characteristic sites of involvement are skin and central nervous system and although an ante-mortem diagnosis can be made from a biopsy specimen, it is often unsuspected [4]. We present a case of angiotropic large B-cell lymphoma in a 74-year-old man who presented with urinary symptoms and had a neurological picture resembling subacute combined degeneration of the cord.

Entities:  

Mesh:

Year:  1999        PMID: 10622461     DOI: 10.1016/s0303-8467(99)00063-3

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Paraplegia and sensory deficit caused by angiotropic large cell lymphoma.

Authors:  Marc Legeais; Sophie Gallas; Jean Philippe Cottier; Denis Herbreteau
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

Review 2.  Subacute cognitive disorders as initial presentation of intravascular lymphoma: a case report and review of literature.

Authors:  Manuela Gioulis; Giampaolo Ben; Paolo Iuzzolino; Francesca De Biasi; Corrado Marchini; Sandro Zambito Marsala
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.